目次

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Product
1.1.2. Workflow
1.1.3. Application
1.1.4. Regional scope
1.1.5. Estimates and forecast timeline
1.2. Research Methodology
1.3. Information Procurement
1.3.1. Purchased database
1.3.2. GVR’s internal database
1.3.3. Secondary sources
1.3.4. Primary research
1.3.5. Details of primary research
1.4. Information or Data Analysis
1.5. Market Formulation & Validation
1.6. Model Details
1.7. List of Secondary Sources
1.8. List of Primary Sources
1.9. Objectives

Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Product
2.2.2. Workflow
2.2.3. Application
2.2.4. Regional outlook
2.3. Competitive Insights

Chapter 3. Japan Contract Development and Manufacturing Organization Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook
3.2. Penetration & Growth Prospect Mapping
3.3. Market Dynamics
3.3.1. Market driver analysis
3.3.2. Market restraint analysis
3.4. Japan Contract Development and Manufacturing Organization Market Analysis Tools
3.4.1. Industry Analysis - Porter’s
3.4.1.1. Supplier power
3.4.1.2. Buyer power
3.4.1.3. Substitution threat
3.4.1.4. Threat of new entrant
3.4.1.5. Competitive rivalry
3.4.2. PESTEL Analysis
3.4.2.1. Political landscape
3.4.2.2. Technological landscape
3.4.2.3. Economic landscape

Chapter 4. Japan Contract Development and Manufacturing Organization: Product Estimates & Trend Analysis
4.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
4.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
4.3. API
4.3.1. API market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2. Type
4.3.2.1. Type market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.2. Traditional active pharmaceutical ingredient (traditional API)
4.3.2.2.1. Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.3. Highly potent active pharmaceutical ingredient (HP-API)
4.3.2.3.1. Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.4. Antibody drug conjugate (ADC)
4.3.2.4.1. Antibody drug conjugate (ADC) market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.2.5. Others
4.3.2.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3. Synthesis
4.3.3.1. Synthesis market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.2. Synthetic
4.3.3.2.1. Synthetic market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.3. Solid
4.3.3.3.1. Solid market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.4. Liquid
4.3.3.4.1. Liquid market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.3.5. Biotech
4.3.3.5.1. Biotech market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4. Drug
4.3.4.1. Drug market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4.2. Innovative
4.3.4.2.1. Innovative market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.4.3. Generic
4.3.4.3.1. Generic market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5. Manufacturing
4.3.5.1. Manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5.2. Continuous manufacturing
4.3.5.2.1. Continuous manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.3.5.3. Batch manufacturing
4.3.5.3.1. Batch manufacturing market estimates and forecasts, 2018 to 2030 (USD Million)
4.4. Drug Product
4.4.1. Drug product market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.2. Oral solid dose
4.4.2.1. Oral solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.3. Semi-solid dose
4.4.3.1. Semi-solid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.4. Liquid dose
4.4.4.1. Liquid dose market estimates and forecasts, 2018 to 2030 (USD Million)
4.4.5. Others
4.4.5.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 5. Japan Contract Development and Manufacturing Organization: Workflow Estimates & Trend Analysis
5.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
5.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
5.3. Clinical
5.3.1. Clinical market estimates and forecasts, 2018 to 2030 (USD Million)
5.4. Commercial
5.4.1. Commercial market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 6. Japan Contract Development and Manufacturing Organization: Application Estimates & Trend Analysis
6.1. Japan Contract Development and Manufacturing Organization Market: Key Takeaways
6.2. Japan Contract Development and Manufacturing Organization Market: Movement & Market Share Analysis, 2022 & 2030
6.3. Oncology
6.3.1. Oncology market estimates and forecasts, 2018 to 2030 (USD Million)
6.4. Hormonal
6.4.1. Hormonal market estimates and forecasts, 2018 to 2030 (USD Million)
6.5. Glaucoma
6.5.1. Glaucoma market estimates and forecasts, 2018 to 2030 (USD Million)
6.6. Cardiovascular Disease
6.6.1. Cardiovascular disease market estimates and forecasts, 2018 to 2030 (USD Million)
6.7. Diabetes
6.7.1. Diabetes delivery market estimates and forecasts, 2018 to 2030 (USD Million)
6.8. Others
6.8.1. Others market estimates and forecasts, 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape
7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Market Participant Categorization
7.2.1. CORDENPHARMA INTERNATIONAL
7.2.1.1. Company overview
7.2.1.2. Financial performance
7.2.1.3. Product benchmarking
7.2.1.4. Strategic initiatives
7.2.2. WuXi AppTec
7.2.2.1. Company overview
7.2.2.2. Financial performance
7.2.2.3. Product benchmarking
7.2.2.4. Strategic initiatives
7.2.3. Cambrex Corporation
7.2.3.1. Company overview
7.2.3.2. Financial performance
7.2.3.3. Product benchmarking
7.2.3.4. Strategic initiatives
7.2.4. Recipharm AB
7.2.4.1. Company overview
7.2.4.2. Financial performance
7.2.4.3. Product benchmarking
7.2.4.4. Strategic initiatives
7.2.5. Lonza
7.2.5.1. Company overview
7.2.5.2. Financial performance
7.2.5.3. Product benchmarking
7.2.5.4. Strategic initiatives
7.2.6. Catalent, Inc.
7.2.6.1. Company overview
7.2.6.2. Financial performance
7.2.6.3. Product benchmarking
7.2.6.4. Strategic initiatives
7.2.7. Laboratory Corporation of America Holdings
7.2.7.1. Company overview
7.2.7.2. Financial performance
7.2.7.3. Product benchmarking
7.2.7.4. Strategic initiatives
7.2.8. Thermo Fisher Scientific, Inc
7.2.8.1. Company overview
7.2.8.2. Financial performance
7.2.8.3. Product benchmarking
7.2.8.4. Strategic initiatives
7.2.9. Samsung BioLogics
7.2.9.1. Company overview
7.2.9.2. Financial performance
7.2.9.3. Product benchmarking
7.2.9.4. Strategic initiatives
7.2.10. FUJIFILM Corporation (FUJIFILM Diosynth Biotechnologies U.S.A.)
7.2.10.1. Company overview
7.2.10.2. Financial performance
7.2.10.3. Product benchmarking
7.2.10.4. Strategic initiatives
7.2.11. SUMITOMO CHEMICAL COMPANY, LIMITED
7.2.11.1. Company overview
7.2.11.2. Financial performance
7.2.11.3. Product benchmarking
7.2.11.4. Strategic initiatives
7.2.12. CMIC HOLDINGS Co., LTD
7.2.12.1. Company overview
7.2.12.2. Financial performance
7.2.12.3. Product benchmarking
7.2.12.4. Strategic initiatives
7.2.13. Bushu Pharmaceuticals LTD.
7.2.13.1. Company overview
7.2.13.2. Financial performance
7.2.13.3. Product benchmarking
7.2.13.4. Strategic initiatives
7.2.14. NIPRO
7.2.14.1. Company overview
7.2.14.2. Financial performance
7.2.14.3. Product benchmarking
7.2.14.4. Strategic initiatives

List of Tables
Table 1 List of Abbreviations
Table 2 Japan contract development and manufacturing organization market, by product, 2018 - 2030 (USD Million)
Table 3 Japan contract development and manufacturing organization market, by workflow, 2018 - 2030 (USD Million)
Table 4 Japa contract development and manufacturing organization market, by application, 2018 - 2030 (USD Million)

List of Figures
Fig. 1 Market research process
Fig. 2 Data triangulation techniques
Fig. 3 Primary research pattern
Fig. 4 Market research approaches
Fig. 5 Value-chain-based sizing & forecasting
Fig. 6 QFD modeling for market share assessment
Fig. 7 Market formulation & validation
Fig. 8 Japan contract development and manufacturing organization: Market outlook
Fig. 9 Japan contract development and manufacturing organization: Competitive insights
Fig. 10 Parent market outlook
Fig. 11 Related/ancillary market outlook
Fig. 12 Penetration and growth prospect mapping
Fig. 13 Industry value chain analysis
Fig. 14 Japan contract development and manufacturing organization market driver impact
Fig. 15 Japan contract development and manufacturing organization market restraint impact
Fig. 16 Japan contract development and manufacturing organization market strategic initiatives analysis
Fig. 17 Japan contract development and manufacturing organization market: Product movement analysis
Fig. 18 Japan contract development and manufacturing organization market: Product outlook and key takeaways
Fig. 19 API market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 20 Type market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 21 Traditional active pharmaceutical ingredient (traditional API) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 22 Highly potent active pharmaceutical ingredient (HP-API) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 23 Antibody drug conjugate (ADC) market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 24 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 25 Synthesis market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 26 Synthetic market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 27 Solid market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 28 Liquid market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 29 Biotech market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 30 Drug market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 31 Innovative market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 32 Generic market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 33 Manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 34 Continuous manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 35 Batch manufacturing market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 36 Drug product market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 37 Oral solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 38 Semi-solid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 39 Liquid dose market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 40 Others market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 41 Japan contract development and manufacturing organization market: Workflow movement analysis
Fig. 42 Japan contract development and manufacturing organization market: Workflow outlook and key takeaways
Fig. 43 Clinical market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 44 Commercial market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 45 Japan contract development and manufacturing organization market: Application movement analysis
Fig. 46 Japan contract development and manufacturing organization market: Application outlook and key takeaways
Fig. 47 Oncology market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 48 Hormonal market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 49 Glaucoma market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 50 Cardiovascular disease market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 51 Diabetes market estimates and forecasts, 2018 - 2030 (USD Million)
Fig. 52 Others market estimates and forecasts, 2018 - 2030 (USD Million)